{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:46:04Z","timestamp":1789782364423,"version":"4.0.1"},"reference-count":114,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100004541","name":"Ministry of Human Resource Development","doi-asserted-by":"publisher","award":["MHRD-RUSA 2.0-F.24\/51\/2014-U"],"award-info":[{"award-number":["MHRD-RUSA 2.0-F.24\/51\/2014-U"]}],"id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A2B3011676"],"award-info":[{"award-number":["2017R1A2B3011676"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A4A1014806"],"award-info":[{"award-number":["2017R1A4A1014806"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2013M3A6A8073184"],"award-info":[{"award-number":["2013M3A6A8073184"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2019,12,20]]},"abstract":"<jats:sec>\n<jats:title>Background::<\/jats:title>\n<jats:p>Hypertension is a prevalent cardiovascular complication caused by genetic\nand nongenetic factors. Blood pressure (BP) management is difficult because most patients become\nresistant to monotherapy soon after treatment initiation. Although many antihypertensive drugs are\navailable, some patients do not respond to multiple drugs. Identification of personalized antihypertensive\ntreatments is a key for better BP management.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective::<\/jats:title>\n<jats:p> This review aimed to elucidate aspects of rational drug design and other methods to develop\nbetter hypertension management.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results::<\/jats:title>\n<jats:p>Among hypertension-related signaling mechanisms, the renin-angiotensin-aldosterone system\nis the leading genetic target for hypertension treatment. Identifying a single drug that acts on multiple\ntargets is an emerging strategy for hypertension treatment, and could be achieved by discovering new\ndrug targets with less mutated and highly conserved regions. Extending pharmacogenomics research\nto include patients with hypertension receiving multiple antihypertensive drugs could help identify the\ngenetic markers of hypertension. However, available evidence on the role of pharmacogenomics in\nhypertension is limited and primarily focused on candidate genes. Studies on hypertension pharmacogenomics\naim to identify the genetic causes of response variations to antihypertensive drugs. Genetic\nassociation studies have identified single nucleotide polymorphisms affecting drug responses. To understand\nhow genetic traits alter drug responses, computational screening of mutagenesis can be utilized\nto observe drug response variations at the protein level, which can help identify new inhibitors\nand drug targets to manage hypertension.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions::<\/jats:title>\n<jats:p>Rational drug design facilitates the discovery and design of potent inhibitors. However,\nfurther research and clinical validation are required before novel inhibitors can be clinically used as\nantihypertensive therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450120666190808101356","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T08:46:09Z","timestamp":1565253969000},"page":"18-33","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies"],"prefix":"10.2174","volume":"21","author":[{"given":"Lakshmanan","family":"Loganathan","sequence":"first","affiliation":[{"name":"Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnasamy","family":"Gopinath","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering, Konkuk University, 1 Hwayang-Dong, Gwangjin-Gu, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadivel Murugan","family":"Sankaranarayanan","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Velammal Medical College Hospital and Research Institute, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritushree","family":"Kukreti","sequence":"additional","affiliation":[{"name":"Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-6515","authenticated-orcid":true,"given":"Kannan","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Saveetha Medical College and Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Kul","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering, Konkuk University, 1 Hwayang-Dong, Gwangjin-Gu, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7755-3381","authenticated-orcid":true,"given":"Karthikeyan","family":"Muthusamy","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"WHO. Global Health Observatory (GHO) data [homepage on the Internet]. World Heal Organ. (Accessed November 04, 2018)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"Benjamin E.J.","year":"2018","unstructured":"Benjamin E.J.; Virani S.S.; Callaway C.W.; American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2018 update: A report from the american heart association. Circulation 2018,137(12),e67-e492","journal-title":"Circulation"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s11906-015-0586-5","volume":"17","author":"Arwood M.J.","year":"2015","unstructured":"Arwood M.J.; Cavallari L.H.; Duarte J.D.; Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep 2015,17(9),586","journal-title":"Curr Hypertens Rep"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","volume":"69","author":"Williams B.","year":"2017","unstructured":"Williams B.; Cockcroft J.R.; Kario K.; Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The parameter study. Hypertension 2017,69(3),411-420","journal-title":"Hypertension"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2005.05.016","volume":"25","author":"Toto R.D.","year":"2005","unstructured":"Toto R.D.; Treatment of hypertension in chronic kidney disease. Semin Nephrol 2005,25(6),435-439","journal-title":"Semin Nephrol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/0973-7847.79097","volume":"5","author":"Tabassum N.","year":"2011","unstructured":"Tabassum N.; Ahmad F.; Role of natural herbs in the treatment of hypertension. Pharmacogn Rev 2011,5(9),30-40","journal-title":"Pharmacogn Rev"},{"key":"ref=7","author":"Vm M","year":"2017","unstructured":"Vm M; Kak L; Pm F; Bassett K; Jm W;  Blood pressure lowering\nefficacy of renin inhibitors for primary hypertension ( Review )\nSummary of Findings for the Main Comparison Cochrane Database\nSyst Rev  (4)2017"},{"key":"ref=8","first-page":"41","author":"Shrout T.","year":"2017","unstructured":"Shrout T.; Rudy D.W.; Piascik M.T.;  Hypertension update, JNC8 and beyond current opinion in pharmacology 2017,41-46","journal-title":"Hypertension update, JNC8 and beyond current opinion in pharmacology"},{"key":"ref=9","first-page":"3243","volume":"17","author":"Rose R.","year":"2011","unstructured":"Rose R.; Balakrishnan A.; Muthusamy K.; Arumugam P.; Shanmugam S.; Gopalswamy J.; Myocilin mutations among POAG patients from two populations of Tamil Nadu, South India, a comparative analysis. Mol Vis 2011,17(December),3243-3253","journal-title":"Mol Vis"},{"key":"ref=10","first-page":"73","author":"Gupta R.","year":"2004","unstructured":"Gupta R.;  Trends in Hypertension Epidemiology in India 2004,73-8","journal-title":"Trends in Hypertension Epidemiology in India"},{"key":"ref=11","year":"2017","unstructured":"Cover Story _ The 2017 High Blood Pressure Guideline_ Risk\n   Reduction Through Better Management - American College of\n  Cardiology American College of Cardiology 2017","journal-title":"Cover Story _ The 2017 High Blood Pressure Guideline_ Risk\n   Reduction Through Better Management - American College of\n  Cardiology American College of Cardiology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jch.13145","volume":"20","author":"Kario K.","year":"2018","unstructured":"Kario K.; Tomitani N.; Buranakitjaroen P.; HOPE Asia Network. Rationale and design for the Asia BP@Home study on home blood pressure control status in 12 Asian countries and regions. J Clin Hypertens (Greenwich) 2018,20(1),33-38","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=13","author":"Dymond J.N.","year":"1972","unstructured":"Dymond J.N.; Rarities C.;  Bird Report Systematic List 1976Vol. 391972","journal-title":"Bird Report"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3349\/ymj.2018.59.3.356","volume":"59","author":"Kim T.J.","year":"2018","unstructured":"Kim T.J.; Lee J.W.; Kang H.T.; Trends in Blood Pressure and Prevalence of Hypertension in Korean Adults Based on the 1998-2014 KNHANES. Yonsei Med J 2018,59(3),356-365","journal-title":"Yonsei Med J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","volume":"71","author":"Ohno Y.","year":"2018","unstructured":"Ohno Y.; Sone M.; Inagaki N.; Nagahama study JPAS study group. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: A multicenter study in japan. Hypertension 2018,71(3),530-537","journal-title":"Hypertension"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1524-6175.2006.05116.x","volume":"8","author":"Franklin S.S.","year":"2006","unstructured":"Franklin S.S.; Hypertension in older people: part 2. J Clin Hypertens (Greenwich) 2006,8(7),521-525","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jama.1997.03550130039034","volume":"278","author":"Staessen J.A.","year":"1997","unstructured":"Staessen J.A.; Byttebier G.; Buntinx F.; Celis H.; O\u2019Brien E.T.; Fagard R.; Ambulatory blood pressure monitoring and treatment of hypertension investigators. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. JAMA 1997,278(13),1065-1072","journal-title":"JAMA"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199311113292001","volume":"329","author":"Baker M.D.","year":"1993","unstructured":"Baker M.D.; Bell L.M.A.J.; The new england journal of medicine downloaded from Nejm.Org at GEORGE WASHINGTON UNIVERSITY on March 4, 2012. For personal use only. No other uses without permission. Copyright  1993 Massachusetts medical society. All Rights Reserved. N Engl J Med 1993,329(20),1437-1441","journal-title":"N Engl J Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2217\/pgs.15.131","volume":"16","author":"Lupoli S.","year":"2015","unstructured":"Lupoli S.; Salvi E.; Barcella M.; Barlassina C.; Pharmacogenomics considerations in the control of hypertension. Pharmacogenomics 2015,16(17),1951-1964","journal-title":"Pharmacogenomics"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00007611-198808000-00033","volume":"81","author":"Fox L.S.","year":"1988","unstructured":"Fox L.S.; Schooley W.R.; Nichols R.L.; Webb W.R.; Open cardiac operations in patients with abnormalities of white blood cell number or function. South Med J 1988,81(8),1065-1066","journal-title":"South Med J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/archinte.160.4.494","volume":"160","author":"Wassertheil-Smoller S.","year":"2000","unstructured":"Wassertheil-Smoller S.; Fann C.; Allman R.M.; Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Arch Intern Med The SHEP Cooperative Research Group2000,160(4),494-500","journal-title":"Arch Intern Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjhyper.2003.08.015","volume":"17","author":"Alderman M.H.","year":"2004","unstructured":"Alderman M.H.; Cohen H.W.; Sealey J.E.; Laragh J.H.; Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004,17(1),1-7","journal-title":"Am J Hypertens"},{"key":"ref=23","first-page":"333","volume":"6","author":"Banic A.","year":"2018","unstructured":"Banic A.; Benkovic V.; Knezevic A.; Effectiveness of hypertension therapy by using fixed combinations and monocomponent drugs - A prospective study from croatia. J Pharm Pharmacol 2018,6,333-339","journal-title":"J Pharm Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/jch.13094","volume":"19","author":"Mehanna M.","year":"2017","unstructured":"Mehanna M.; Gong Y.; McDonough C.W.; Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. J Clin Hypertens (Greenwich) 2017,19(12),1301-1308","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.115.06345","volume":"67","author":"Gong Y.","year":"2016","unstructured":"Gong Y.; Wang Z.; Beitelshees A.L.; Pharmacogenomic genome-wide meta-analysis of blood pressure response to \u03b2-blockers in hypertensive african americans. Hypertension 2016,67(3),556-563","journal-title":"Hypertension"},{"key":"ref=26","first-page":"57","author":"Baker J.H.","year":"2018","unstructured":"Baker J.H.;  Meditation for Reducing CVD Risk 2018,57-60","journal-title":"Meditation for Reducing CVD Risk"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.mayocp.2015.03.016","volume":"90","author":"Kaufman A.L.","year":"2015","unstructured":"Kaufman A.L.; Spitz J.; Jacobs M.; Evidence for clinical implementation of pharmacogenomics in cardiac drugs. Mayo Clin Proc 2015,90(6),716-729","journal-title":"Mayo Clin Proc"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev-pharmtox-010814-124446","volume":"55","author":"Feldman R.D.","year":"2015","unstructured":"Feldman R.D.; Hussain Y.; Kuyper L.M.; McAlister F.A.; Padwal R.S.; Tobe S.W.; Intraclass differences among antihypertensive drugs. Annu Rev Pharmacol Toxicol 2015,55(1),333-352","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.2147\/DDDT.S134826","volume":"11","author":"Guasti L.","year":"2017","unstructured":"Guasti L.; Gaudio G.; Lupi A.; Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors\/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients. Drug Des Devel Ther 2017,11,2293-2300","journal-title":"Drug Des Devel Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/HJH.0000000000000574","volume":"33","author":"Menni C.","year":"2015","unstructured":"Menni C.; Blood pressure pharmacogenomics: gazing into a misty crystal ball. J Hypertens 2015,33(6),1142-1143","journal-title":"J Hypertens"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrneph.2015.176","volume":"12","author":"Cooper-DeHoff R.M.","year":"2016","unstructured":"Cooper-DeHoff R.M.; Johnson J.A.; Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol 2016,12(2),110-122","journal-title":"Nat Rev Nephrol"},{"key":"ref=32","first-page":"148","volume":"17","author":"Barton Laws M","year":"2013","unstructured":"Barton Laws M; Beach M C; Lee Y; The pharmacogenomics\nresearch network translational pharmacogenetics program: Overcoming\nchallenges of real- world implementation NIH public access 2013,17(1),148-59"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/1875692113666150420225829","volume":"12","author":"Singh K.D.","year":"2015","unstructured":"Singh K.D.; Jajodia A.; Kaur H.; Kukreti R.; Karthikeyan M.; Renin angiotensin system gene polymorphisms in response to antihypertensive drugs and visit-to-visit blood pressure variability in essential hypertensive patients. Curr Pharmacogenomics Person Med 2015,12(4),227-235","journal-title":"Curr Pharmacogenomics Person Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/HJH.0000000000001159","volume":"35","author":"Wang J.","year":"2017","unstructured":"Wang J.; Shi X.; Ma C.; Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2017,35(1),10-17","journal-title":"J Hypertens"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ajh\/hpw106","volume":"30","author":"Wu C.","year":"2017","unstructured":"Wu C.; Shlipak M.G.; Stawski R.S.; Health ABC study. Visit-to-visit blood pressure variability and mortality and cardiovascular outcomes among older adults: The health, aging, and body composition study. Am J Hypertens 2017,30(2),151-158","journal-title":"Am J Hypertens"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171745","volume":"12","author":"Dumitrescu L.","year":"2017","unstructured":"Dumitrescu L.; Ritchie M.D.; Denny J.C.; Genome-wide study of resistant hypertension identified from electronic health records. PLoS One 2017,12(2)","journal-title":"PLoS One"},{"key":"ref=37","first-page":"129","volume":"20","author":"Chern T.H.","year":"2004","unstructured":"Chern T.H.; Chiang F.T.; Molecular genetic study of hypertension. Acta Cardiol Sin 2004,20(3),129-138","journal-title":"Acta Cardiol Sin"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1152\/physrev.1990.70.4.1067","volume":"70","author":"Hackenthal E.","year":"1990","unstructured":"Hackenthal E.; Paul M.; Ganten D.; Taugner R.; Morphology, physiology and molecular biology of renin secretion. Physiol Rev 1990,70(4),1067-1116","journal-title":"Physiol Rev"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"Fyhrquist F.","year":"2008","unstructured":"Fyhrquist F.; Saijonmaa O.; Renin-angiotensin system revisited. J Intern Med 2008,264(3),224-236","journal-title":"J Intern Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/sj.jhh.1001043","volume":"14","author":"Lee W.K.","year":"2000","unstructured":"Lee W.K.; Padmanabhan S.; Dominiczak A.F.; Genetics of hypertension: from experimental models to clinical applications. J Hum Hypertens 2000,14(10-11),631-647","journal-title":"J Hum Hypertens"},{"key":"ref=41","first-page":"65","volume":"19","author":"Gautam N.","year":"2018","unstructured":"Gautam N.; Kaur S.; Kaur S.; Kumar S.; Computational Study of ACE and AGT Gene of RAAS Pathway. World News Nat Sci 2018,19(June),65-77","journal-title":"World News Nat Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jlumin.2018.06.085","volume":"203","author":"Alanazi A.M.","year":"2018","unstructured":"Alanazi A.M.; Abdelhameed A.S.; Bakheit A.H.; Spectroscopic and Molecular Docking Studies of the Binding of the Angiotensin II Receptor Blockers (ARBs) Azilsartan, Eprosartan and Olmesartan to Bovine Serum Albumin. J Lumin 2018,203,616-628","journal-title":"J Lumin"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09723757.2009.11886056","volume":"9","author":"Karthikeyan M.","year":"2009","unstructured":"Karthikeyan M.; Rose R.; Shridevi V.; Core promoter variants (A-20C, T-18C and G-6A) of the angiotensinogen (AGT) gene are not significantly associated with hypertension in patients of tamilnadu, India. Int J Hum Genet 2009,9(1),13-19","journal-title":"Int J Hum Genet"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000455005","volume":"20","author":"Rae K.M.","year":"2017","unstructured":"Rae K.M.; Grimson S.; Pringle K.G.; Personalised medicine: A new approach to improving health in indigenous australian populations. Public Health Genomics 2017,20(1),58-62","journal-title":"Public Health Genomics"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/10641963.2016.1267201","volume":"39","author":"Zhang H.","year":"2017","unstructured":"Zhang H.; Jin L.; Mu T.; Associations of CYP4A11 gene-gene and gene-smoking interactions with essential hypertension in the male eastern Chinese Han population. Clin Exp Hypertens 2017,39(5),448-453","journal-title":"Clin Exp Hypertens"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1592\/phco.29.2.193","volume":"29","author":"Sanoski C.A.","year":"2009","unstructured":"Sanoski C.A.; Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009,29(2),193-212","journal-title":"Pharmacotherapy"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1161\/01.RES.83.12.1182","volume":"83","author":"Matsubara H.","year":"1998","unstructured":"Matsubara H.; Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998,83(12),1182-1191","journal-title":"Circ Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1381612820666141024151119","volume":"21","author":"Zisaki A.","year":"2015","unstructured":"Zisaki A.; Miskovic L.; Hatzimanikatis V.; Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des 2015,21(6),806-822","journal-title":"Curr Pharm Des"},{"key":"ref=49","author":"Durdagi S.","year":"2018","unstructured":"Durdagi S.; Erol I.; Salmas R.E.; Aksoydan B.; Kantarcioglu I.; Oligomerization and Cooperativity in GPCRs from the Perspective of the Angiotensin AT1 and Dopamine D2 Receptors. Neurosci Lett 2018","journal-title":"Neurosci Lett"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1050-1738(98)00022-X","volume":"8","author":"Feldman R.D.","year":"1998","unstructured":"Feldman R.D.; Gros R.; Impaired vasodilator function in hypertension: the role of alterations in receptor-G protein coupling. Trends Cardiovasc Med 1998,8(7),297-305","journal-title":"Trends Cardiovasc Med"},{"key":"ref=51","first-page":"790","volume":"6","author":"Brinks H.L.","year":"2015","unstructured":"Brinks H.L.; Eckhart A.D.; Regulation of GPCR Signaling in Hypertension. Biochim Biophys Acta 2015,6(9),790-795","journal-title":"Biochim Biophys Acta"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1423-0127-20-69","volume":"20","author":"Majzunova M.","year":"2013","unstructured":"Majzunova M.; Dovinova I.; Barancik M.; Chan J.Y.H.; Redox signaling in pathophysiology of hypertension. J Biomed Sci 2013,20(69),69","journal-title":"J Biomed Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cardiores.2006.05.001","volume":"71","author":"Paravicini T.M.","year":"2006","unstructured":"Paravicini T.M.; Touyz R.M.; Redox signaling in hypertension. Cardiovasc Res 2006,71(2),247-258","journal-title":"Cardiovasc Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2174\/0929867323666161213160440","volume":"24","author":"Giorgini P.","year":"2017","unstructured":"Giorgini P.; Sahebkar A.; Stamerra C.A.; Comparison of clinical outcomes between genders following antihypertensive therapy: A meta-analysis. Curr Med Chem 2017,24(24),2639-2649","journal-title":"Curr Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2174\/0929867323666151221150052","volume":"23","author":"Divac N.","year":"2016","unstructured":"Divac N.; Naumovi\u0107 R.; Stojanovi\u0107 R.; Prostran M.; The role of immunosuppressive medications in the pathogenesis of hypertension and efficacy and safety of antihypertensive agents in kidney transplant recipients. Curr Med Chem 2016,23(19),1941-1952","journal-title":"Curr Med Chem"},{"key":"ref=56","first-page":"4","year":"2018","unstructured":"Cruz; J. N.; Oliveira, M. S.; Vogado, J. H.; Silva, S. G.; Costa, W. A.; Fernanda, WF Bezerra; Renato, A. C.; Junior, R. N.; Neto, A. M. Molecular insights on the interactions of nitrosamines from cigarette smoking with CYP2A13 using molecular docking and molecular dynamics simulation HSOA J Pulm Med. Respir Res 2018(August),4","journal-title":"Respir Res"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006150","volume":"96","author":"Wen H","year":"2017 March;","unstructured":"Wen H; Wang L; Reducing effect of aerobic exercise on blood pressure of essential hypertensive patients.  Medicine (United\nStates) 2017 March;,96(11)","journal-title":"Medicine (United\nStates)"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"Turnbull F.","year":"2003","unstructured":"Turnbull F.; Neal B.; Algert C.; Blood pressure lowering treatment trialists\u2019 collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003,362(9395),1527-1535","journal-title":"Lancet"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"Cushman W.C.","year":"2002","unstructured":"Cushman W.C.; Ford C.E.; Cutler J.A.; Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) ALLHAT Collaborative Research Group2002,4(6),393-404","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"Law M.R.","year":"2003","unstructured":"Law M.R.; Wald N.J.; Morris J.K.; Jordan R.E.; Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003,326(7404),1427-0","journal-title":"BMJ"},{"key":"ref=61","first-page":"2391","volume":"64","author":"Davison K.K.","year":"2008","unstructured":"Davison K.K.; Birch L.L.; Oral direct renin inhibition: Premise, promise, and potential limitations of a new class of antihypertensive drug. Am J Med 2008,64(12),2391-2404","journal-title":"Am J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.18553\/jmcp.2007.13.s8-b.21","volume":"13","author":"Pool J.L.","year":"2007","unstructured":"Pool J.L.; Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007,13(8)(Suppl. B),21-33","journal-title":"J Manag Care Pharm"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/01.NAJ.0000532077.64748.d2","volume":"118","author":"Pich J.","year":"2018","unstructured":"Pich J.; The efficacy of renin inhibitors in primary hypertension. Am J Nurs 2018,118(4),56","journal-title":"Am J Nurs"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.atherosclerosis.2015.08.009","volume":"242","author":"Desjarlais M.","year":"2015","unstructured":"Desjarlais M.; Dussault S.; Dhahri W.; Mathieu R.; Rivard A.; Direct renin inhibition with aliskiren improves ischemia-induced neovascularization: blood pressure-independent effect. Atherosclerosis 2015,242(2),450-460","journal-title":"Atherosclerosis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1177\/1470320313514123","volume":"16","author":"Hsu C.N.","year":"2015","unstructured":"Hsu C.N.; Lee C.T.; Huang L.T.; Tain Y.L.; Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction. J Renin Angiotensin Aldosterone Syst 2015,16(3),506-513","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=66","first-page":"623","volume":"60","author":"Buczko W.","year":"2008","unstructured":"Buczko W.; Hermanowicz J.M.; Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008,60(5),623-631","journal-title":"Pharmacol Rep"},{"key":"ref=67","author":"Jm W","year":"2018","unstructured":"Jm W; Vm M; Gill R; First-line drugs for hypertension (Review).\n Summary of findings for the main comparison 2018"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","volume":"43","author":"Carter B.L.","year":"2004","unstructured":"Carter B.L.; Ernst M.E.; Cohen J.D.; Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004,43(1),4-9","journal-title":"Hypertension"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","volume":"48","author":"Zillich A.J.","year":"2006","unstructured":"Zillich A.J.; Garg J.; Basu S.; Bakris G.L.; Carter B.L.; Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006,48(2),219-224","journal-title":"Hypertension"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3949\/ccjm.67.4.287","volume":"67","author":"Hoogwerf B.J.","year":"2000","unstructured":"Hoogwerf B.J.; Young J.B.; The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve Clin J Med 2000,67(4),287-293","journal-title":"Cleve Clin J Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.mehy.2009.01.012","volume":"72","author":"Fein A.","year":"2009","unstructured":"Fein A.; ACE inhibitors worsen inflammatory pain. Med Hypotheses 2009,72(6),757","journal-title":"Med Hypotheses"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.amjcard.2010.08.023","volume":"106","author":"Ram C.V.S.","year":"2010","unstructured":"Ram C.V.S.; Beta-blockers in hypertension. Am J Cardiol 2010,106(12),1819-1825","journal-title":"Am J Cardiol"},{"key":"ref=73","author":"Quinn U.","year":"2017","unstructured":"Quinn U.;  Renin genotype as a predictor of response to antihypertensive therapy\u202f: A personalized approach to management of high blood pressure R Coll Surg Irel 2017","journal-title":"Renin genotype as a predictor of response to antihypertensive therapy\u202f: A personalized approach to management of high blood pressure R Coll Surg Irel"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14656566.2017.1288719","volume":"18","author":"Rochlani Y.","year":"2017","unstructured":"Rochlani Y.; Khan M.H.; Banach M.; Aronow W.S.; Are two drugs better than one? A review of combination therapies for hypertension. Expert Opin Pharmacother 2017,18(4),377-386","journal-title":"Expert Opin Pharmacother"},{"key":"ref=75","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/538053","volume":"\u2022","year":"2014","unstructured":"Jajodia A, Kaur H, Kukreti R, Karthikeyan M. Gender specific association of RAS gene polymorphism with essential hypertension: a case-control study. BioMed Res Int Dhanachandra Singh Kh2014,\u2022","journal-title":"BioMed Res Int"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","volume":"114","author":"Strauss M.H.","year":"2006","unstructured":"Strauss M.H.; Hall A.S.; Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006,114(8),838-854","journal-title":"Circulation"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jash.2007.04.004","volume":"1","author":"Weir M.R.","year":"2007","unstructured":"Weir M.R.; Bush C.; Anderson D.R.; Zhang J.; Keefe D.; Satlin A.; Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007,1(4),264-277","journal-title":"J Am Soc Hypertens"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000028.pub2","author":"Musini V.M.","year":"2009","unstructured":"Musini V.M.; Tejani A.M.; Bassett K.; Wright J.M.; Pharmacotherapy for Hypertension in the Elderly. Cochrane Database Syst Rev 2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=79","year":"2018","unstructured":"Food and drug administration (FDA). Hypertension: developing\n fixed- dose combination drugs for treatment guidance for industry\n Center for Drug Evaluation Research. CDER 2018"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1021\/ci000403i","volume":"41","author":"Hann M.M.","year":"2001","unstructured":"Hann M.M.; Leach A.R.; Harper G.; Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 2001,41(3),856-864","journal-title":"J Chem Inf Comput Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/90765","volume":"19","author":"Myers S.","year":"2001","unstructured":"Myers S.; Baker A.; Drug discovery--an operating model for a new era. Nat Biotechnol 2001,19(8),727-730","journal-title":"Nat Biotechnol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","volume":"22","author":"DiMasi J.A.","year":"2003","unstructured":"DiMasi J.A.; Hansen R.W.; Grabowski H.G.; The price of innovation: new estimates of drug development costs. J Health Econ 2003,22(2),151-185","journal-title":"J Health Econ"},{"key":"ref=83","first-page":"488","volume":"159","author":"McAlister F.A.","year":"1998","unstructured":"McAlister F.A.; Straus S.; Sackett D.; Randomized clinical trials of antihypertensive drugs: all that glitters is not gold. CMAJ 1998,159(5),488-490","journal-title":"CMAJ"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0253-7613.75659","volume":"43","author":"Chakraborty B.S.","year":"2011","unstructured":"Chakraborty B.S.; Clinical trials of antihypertensives: Nature of control and design. Indian J Pharmacol 2011,43(1),13-17","journal-title":"Indian J Pharmacol"},{"key":"ref=85","first-page":"25","author":"Karaman B.","year":"2018","unstructured":"Karaman B.; Sippl W.; Computational Drug Repurposing: Current Trends. Curr Med Chem 2018,25","journal-title":"Curr Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.csbj.2016.04.004","volume":"14","author":"Katsila T.","year":"2016","unstructured":"Katsila T.; Spyroulias G.A.; Patrinos G.P.; Matsoukas M.T.; Computational approaches in target identification and drug discovery. Comput Struct Biotechnol J 2016,14,177-184","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/384023a0","volume":"384","author":"Blundell T.L.","year":"1996","unstructured":"Blundell T.L.; Structure-based drug design. Nature 1996,384(6604)(Suppl.),23-26","journal-title":"Nature"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.bbamem.2015.04.016","volume":"1848","author":"Yousefpour A.","year":"2015","unstructured":"Yousefpour A.; Modarress H.; Goharpey F.; Amjad-Iranagh S.; Interaction of PEGylated anti-hypertensive drugs, amlodipine, atenolol and lisinopril with lipid bilayer membrane: A molecular dynamics simulation study. Biochim Biophys Acta 2015,1848(8),1687-1698","journal-title":"Biochim Biophys Acta"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1016\/j.bmcl.2017.11.003","volume":"27","author":"Wang Z.","year":"2017","unstructured":"Wang Z.; Cheng L.P.; Zhang X.H.; Pang W.; Li L.; Zhao J.L.; Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors. Bioorg Med Chem Lett 2017,27(24),5429-5435","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1570180815666180827113622","author":"Loganathan L.","year":"2018","unstructured":"Loganathan L.; Muthusamy K.; Investigation of Drug Interaction Potentials and Binding Modes on Direct Renin Inhibitors. A Computational Modeling Studies. Lett Drug Des Discov 2018,15","journal-title":"Lett Drug Des Discov"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.foodchem.2016.10.087","volume":"221","author":"Garc\u00eda-Mora P.","year":"2017","unstructured":"Garc\u00eda-Mora P.; Mart\u00edn-Mart\u00ednez M.; Angeles Bonache M.; Identification, functional gastrointestinal stability and molecular docking studies of lentil peptides with dual antioxidant and angiotensin I converting enzyme inhibitory activities. Food Chem 2017,221,464-472","journal-title":"Food Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12539-017-0243-6","volume":"10","author":"Arya H.","year":"2018","unstructured":"Arya H.; Syed S.B.; Singh S.S.; Ampasala D.R.; Coumar M.S.; \n                        In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5. Interdiscip Sci 2018,10(4),792-804","journal-title":"Interdiscip Sci"},{"key":"ref=93","first-page":"1","volume":"1102","author":"Kecel-G\u00fcnd\u00fcz S.","year":"2017","unstructured":"Kecel-G\u00fcnd\u00fcz S.; Budama-Kilinc Y.; Cakir Koc R.; Computational design of Phe-tyr dipeptide and preparation, characterization, cytotoxicity studies of Phe-tyr dipeptide loaded PLGA nanoparticles for the treatment of hypertension. J Biomol Struct Dyn 2017,1102(August),1-15","journal-title":"J Biomol Struct Dyn"},{"key":"ref=94","doi-asserted-by":"publisher","DOI":"10.3390\/md16090299","volume":"16","author":"Deng Z.","year":"2018","unstructured":"Deng Z.; Liu Y.; Wang J.; Antihypertensive effects of two novel angiotensin I-converting enzyme (ACE) inhibitory peptides from Gracilariopsis lemaneiformis (Rhodophyta) in spontaneously hypertensive rats (SHRs). Mar Drugs 2018,16(9)","journal-title":"Mar Drugs"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.5530\/jyp.2018.2s.7","volume":"10","author":"Triputra M.A.","year":"2018","unstructured":"Triputra M.A.; Yanuar A.; Analysis of compounds isolated from gnetum gnemon L. Seeds as potential ACE inhibitors through molecular docking and molecular dynamics simulations. J Young Pharm 2018,10(2s),S32-S39","journal-title":"J Young Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamaoncol.2016.3478","volume":"3","author":"Walsh C.G.","year":"2017","unstructured":"Walsh C.G.; Johnson K.B.; Observational cohort studies and the challenges of in silico experiments. JAMA Oncol 2017,3(1),55-57","journal-title":"JAMA Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/aps.2013.129","volume":"34","author":"Singh K.D.","year":"2013","unstructured":"Singh K.D.; Muthusamy K.; Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imidazole series as dual AT(1) and ET(A) receptor antagonists. Acta Pharmacol Sin 2013,34(12),1592-1606","journal-title":"Acta Pharmacol Sin"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/med.21483","volume":"38","author":"Zheng M.","year":"2018","unstructured":"Zheng M.; Zhao J.; Cui C.; Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies. Med Res Rev 2018,38(3),914-950","journal-title":"Med Res Rev"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"Kircher M.","year":"2014","unstructured":"Kircher M.; Witten D.M.; Jain P.; O\u2019Roak B.J.; Cooper G.M.; Shendure J.; A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014,46(3),310-315","journal-title":"Nat Genet"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.2174\/0929867323666160926150617","volume":"23","author":"Karahalil B.","year":"2016","unstructured":"Karahalil B.; Overview of Systems Biology and Omics Technologies. Curr Med Chem 2016,23(37),4221-4230","journal-title":"Curr Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"Lek M.","year":"2016","unstructured":"Lek M.; Karczewski K.J.; Minikel E.V.; Analysis of protein-coding genetic variation in 60,706 humans. Nature Exome Aggregation Consortium2016,536(7616),285-291","journal-title":"Nature"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/10799893.2014.922575","volume":"34","author":"Singh KhD.","year":"2014","unstructured":"Singh KhD.; Karthikeyan M.; Combined sequence and sequence-structure-based methods for analyzing RAAS gene SNPs: a computational approach. J Recept Signal Transduct Res 2014,34(6),513-526","journal-title":"J Recept Signal Transduct Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mgene.2016.03.005","volume":"9","author":"Nagamani S.","year":"2016","unstructured":"Nagamani S.; Singh KhD.; Muthusamy K.; Combined sequence and sequence-structure based methods for analyzing FGF23, CYP24A1 and VDR genes. Meta Gene 2016,9,26-36","journal-title":"Meta Gene"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/humu.22","volume":"17","author":"Wang Z.","year":"2001","unstructured":"Wang Z.; Moult J.; SNPs, protein structure, and disease. Hum Mutat 2001,17(4),263-270","journal-title":"Hum Mutat"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1093\/hmg\/10.21.2319","volume":"10","author":"Miller M.P.","year":"2001","unstructured":"Miller M.P.; Kumar S.; Understanding human disease mutations through the use of interspecific genetic variation. Hum Mol Genet 2001,10(21),2319-2328","journal-title":"Hum Mol Genet"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/nar\/gkw1064","volume":"45","author":"Sunil K.","year":"2017","unstructured":"Sunil K.; Giovanna A.; Philipp B.; SNP2TFBS-a database of regulatory SNPs affecting predicted transcription factor binding site affinity. Nucleic Acids Res 2017,45(D1),139-144","journal-title":"Nucleic Acids Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jmb.2016.11.022","volume":"429","author":"Xiong P.","year":"2017","unstructured":"Xiong P.; Zhang C.; Zheng W.; Zhang Y.; BindProfX: Assessing mutation-induced binding affinity change by protein interface profiles with pseudo-counts. J Mol Biol 2017,429(3),426-434","journal-title":"J Mol Biol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pbiomolbio.2016.10.002","volume":"128","author":"Jubb H.C.","year":"2017","unstructured":"Jubb H.C.; Pandurangan A.P.; Turner M.A.; Ochoa-Monta\u00f1o B.; Blundell T.L.; Ascher D.B.; Mutations at protein-protein interfaces: Small changes over big surfaces have large impacts on human health. Prog Biophys Mol Biol 2017,128,3-13","journal-title":"Prog Biophys Mol Biol"},{"key":"ref=109","first-page":"797","author":"Patriotis C.","year":"2016","unstructured":"Patriotis C.; Maruvada P.; Srivastava S.;  Molecular Detection and Diagnosis of Cancer 2016,797-809","journal-title":"Molecular Detection and Diagnosis of Cancer"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd1227","volume":"2","author":"Acharya K.R.","year":"2003","unstructured":"Acharya K.R.; Sturrock E.D.; Riordan J.F.; Ehlers M.R.W.; Ace revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2003,2(11),891-902","journal-title":"Nat Rev Drug Discov"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/288280a0","volume":"288","author":"Patchett A.A.","year":"1980","unstructured":"Patchett A.A.; Harris E.; Tristram E.W.; A new class of angiotensin-converting enzyme inhibitors. Nature 1980,288(5788),280-283","journal-title":"Nature"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/363418a0","volume":"363","author":"von Itzstein M.","year":"1993","unstructured":"von Itzstein M.; Wu W.Y.; Kok G.B.; Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993,363(6428),418-423","journal-title":"Nature"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/303041a0","volume":"303","author":"Colman P.M.","year":"1983","unstructured":"Colman P.M.; Varghese J.N.; Laver W.G.; Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983,303(5912),41-44","journal-title":"Nature"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.2174\/1381612824666180810162944","volume":"24","author":"Lu X.","year":"2018","unstructured":"Lu X.; Yang H.; Chen Y.; The development of pharmacophore modeling: Generation and recent applications in drug discovery. Curr Pharm Des 2018,24(29),3424-3439","journal-title":"Curr Pharm Des"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T11:30:14Z","timestamp":1579779014000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174179\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666190808101356","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}